Immediate genomic-to-clinical translation
Processes next-generation sequencing (NGS) panel findings, including complex fusions and biomarkers such as TMB or MSI, and classifies actionability according to AMP/ASCO/CAP.
Biomedical technology for complex clinical decisions
Sphera Innovation develops clinical and molecular decision support platforms for the hospital setting. A multidisciplinary team of clinical specialists together with software and hardware engineers.
Precision oncology
Molecular interpretation oriented towards clinical action, not the isolated data point.
Fully traceable reasoning
Every conclusion documented and linked to its scientific evidence.
Fits the real clinical workflow
Designed around hospital timelines and systems, not the other way round.
Tumor boards work with more data and less time
Every case reaches the tumor board with a growing volume of genomic data from next-generation sequencing (NGS) panels, while clinical guidelines (NCCN, ESMO) are updated continuously. Rigorously assessing the actionability of each finding and the applicable pharmacological criteria means cross-checking multiple sources within very tight turnaround times.
The bottleneck is no longer obtaining the information: it is structuring it in time to decide on solid ground.
- Genomic data from NGS panels
- Continuously updated clinical guidelines
- Pharmacological and safety criteria
Tumor board decision
Sphera OncoCore: clinical decision support for precision oncology
OncoCore structures the genomic, pharmacological and clinical knowledge behind each case and presents it in a traceable form, so that the tumor board can weigh treatment options with all the evidence ordered and verifiable.
Automated drug safety review
Summary of product characteristics from CIMA, EMA and FDA, plus BIFIMED: interactions such as CYP3A pathways or QT risk, toxicity profiles and contraindications.
Proactive handling of uncertainty
Makes explicit the clinical variables still to be confirmed: ECOG performance status, CNS involvement, previous lines of therapy.
Full traceability and auditability
Every statement linked to its source: PMIDs, clinical trials, guidelines. No black boxes.
Modular, scalable architecture
Built in house: interface, output formats and integration logic adapt to each clinical service.
See the system in detail
View all OncoCore capabilitiesOne platform, multiple clinical domains
Sphera is the technological foundation shared by all our developments. OncoCore is the first vertical solution built on it, with an architecture ready to extend to other clinical domains without rebuilding the foundations.
Explore the Sphera platformSolutions for your organisation
Hospitals
Structured support for tumor boards and for oncology, pharmacy and genetics departments.
View solutionsHealth systems
Standardised clinical and molecular reasoning, auditable across an entire care network.
View solutionsPharmaceutical industry
Biomedical platforms and technological collaboration in precision medicine programmes.
View solutionsWe are looking for clinical services to validate the system with
OncoCore is under active development and its knowledge base is consolidated for the comprehensive management of non-small cell lung cancer (NSCLC). We are seeking collaboration with clinical services to evaluate the system in a real-world setting before extending it to other tumour subtypes.
Propose a collaborationOur commitment
OncoCore does not replace clinical judgement: it structures biological and pharmacological knowledge quickly and without bias, so that the board can spend its time on clinical debate and on patient care.
Contact Sphera